TRPV1 and rheumatoid arthritis: Inhibition of TRPV1 function by concomitant CB1 activation and anandamide (AEA)-induced desensitization (atty acid amid hydrolase inhibition) might be a promising strategy to reduce RA disease activity and pain (Lowin and Straub, 2015).